SCHEMBL165429

SCHEMBL165429

O=Cc1cc(OCc2ccccc2)c(C(=O)OCc2ccccc2)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.52
ALDH1A1 P00352 4/20 0.47
TDP1 Q9NUW8 3/20 0.46
HTT P42858 1/20 0.45
NPC1 O15118 2/20 0.44
NFKB1 P19838 2/20 0.44
RAB9A P51151 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
CYP3A4 P08684 2/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 3/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
PTGER1 P34995 1/20 0.43
MCL1 Q07820 1/20 0.43
MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167521 0.85 ALDH1A1 (0.48) POLBALDH1A1TDP1HTTRAB9A
SCHEMBL165087 0.83 ALDH1A1 (0.57) POLBALDH1A1TDP1HTTNPC1
SCHEMBL11840923 0.82 CCNB2 (0.50) ALDH1A1TDP1NPC1NFKB1RAB9A
SCHEMBL23809724 0.82 ALDH1A1 (0.62) POLBALDH1A1TDP1HTTRAB9A
SCHEMBL168177 0.82 MRGPRX4 (0.46) POLBALDH1A1TDP1HTTL3MBTL1
SCHEMBL3612372 0.81 NPC1 (0.49) ALDH1A1NPC1NFKB1RAB9ANFKB2
SCHEMBL23796966 0.80 MEN1 (0.54) HTTTSHRKMT2AMEN1KDM4E
SCHEMBL24983866 0.80 ALDH1A1 (0.58) POLBALDH1A1TDP1HTTRAB9A
SCHEMBL1315281 0.79 ALDH1A1 (0.59) POLBALDH1A1TDP1HTTNPC1
SCHEMBL23796954 0.78 ALDH1A1 (0.66) POLBALDH1A1TDP1HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 POLB 1496/4885ALDH1A1 3544/4885TDP1 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.